Cargando…

The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes

Multigene expression assays are prognostic for recurrence in hormone-receptor positive 2 (HER-2) negative breast cancer, and, in some cases, predictive of benefit from chemotherapy or extended endocrine therapy. The results of these assays may be used to guide treatment recommendations for early HER...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbi, Mali, Makower, Della, Sparano, Joseph A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366126/
https://www.ncbi.nlm.nih.gov/pubmed/34408795
http://dx.doi.org/10.1177/17588359211038467
_version_ 1783738847836766208
author Barbi, Mali
Makower, Della
Sparano, Joseph A.
author_facet Barbi, Mali
Makower, Della
Sparano, Joseph A.
author_sort Barbi, Mali
collection PubMed
description Multigene expression assays are prognostic for recurrence in hormone-receptor positive 2 (HER-2) negative breast cancer, and, in some cases, predictive of benefit from chemotherapy or extended endocrine therapy. The results of these assays may be used to guide treatment recommendations for early HER-2 negative breast cancer. We review the results of trials establishing the clinical utility of several commercially available gene expression assays.
format Online
Article
Text
id pubmed-8366126
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-83661262021-08-17 The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes Barbi, Mali Makower, Della Sparano, Joseph A. Ther Adv Med Oncol Review Multigene expression assays are prognostic for recurrence in hormone-receptor positive 2 (HER-2) negative breast cancer, and, in some cases, predictive of benefit from chemotherapy or extended endocrine therapy. The results of these assays may be used to guide treatment recommendations for early HER-2 negative breast cancer. We review the results of trials establishing the clinical utility of several commercially available gene expression assays. SAGE Publications 2021-08-14 /pmc/articles/PMC8366126/ /pubmed/34408795 http://dx.doi.org/10.1177/17588359211038467 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Barbi, Mali
Makower, Della
Sparano, Joseph A.
The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes
title The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes
title_full The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes
title_fullStr The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes
title_full_unstemmed The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes
title_short The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes
title_sort clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366126/
https://www.ncbi.nlm.nih.gov/pubmed/34408795
http://dx.doi.org/10.1177/17588359211038467
work_keys_str_mv AT barbimali theclinicalutilityofgeneexpressionassaysinbreastcancerpatientswith03involvedlymphnodes
AT makowerdella theclinicalutilityofgeneexpressionassaysinbreastcancerpatientswith03involvedlymphnodes
AT sparanojosepha theclinicalutilityofgeneexpressionassaysinbreastcancerpatientswith03involvedlymphnodes
AT barbimali clinicalutilityofgeneexpressionassaysinbreastcancerpatientswith03involvedlymphnodes
AT makowerdella clinicalutilityofgeneexpressionassaysinbreastcancerpatientswith03involvedlymphnodes
AT sparanojosepha clinicalutilityofgeneexpressionassaysinbreastcancerpatientswith03involvedlymphnodes